Back

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Lipid-lowering therapy and the atheroma Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

2 More presentations in this session

Presentation thumbnail
State-of-the-art lecture in lipid lowering therapy and the atheroma .
Professor S. Nicholls (Melbourne, AU)
Slides Video
Presentation thumbnail
Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial
Doctor K. Koskinas (Bern, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy and the atheroma
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
thumbnail
Congress Presentation
Long-term survival of heFH or ACS patients on PCSK9 targeted therapy based on the real-life data from poland

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources